Richa Redhu Gehlaut1, Godwin Y Dogbey2, Frank L Schwartz3, Cynthia R Marling4, Jay H Shubrook5. 1. Ohio University Heritage College of Osteopathic Medicine/O'Bleness Memorial Hospital, Diabetes Institute, Ohio University, Athens, OH, USA rgehlaut@westernreservehospital.org. 2. Heritage College of Osteopathic Medicine/CORE Research Office, Ohio University, Athens OH, USA. 3. Diabetes Institute, Ohio University, Athens, OH, USA. 4. School of Electrical Engineering and Computer Science, Russ College of Engineering and Technology and the Diabetes Institute, Ohio University, Athens, OH, USA. 5. Touro University California, College of Osteopathic Medicine, Vallejo, CA, USA.
Abstract
BACKGROUND: Hypoglycemia is often the limiting factor for intensive glucose control in diabetes management, however its actual prevalence in type 2 diabetes (T2DM) is not well documented. METHODOLOGY: A total of 108 patients with T2DM wore a continuous glucose monitoring system (CGMS) for 5 days. Rates and patterns of hypoglycemia and glycemic variability (GV) were calculated. Patient and medication factors were correlated with rates, timing, and severity of hypoglycemia. RESULTS: Of the patients, 49.1% had at least 1 hypoglycemic episode (mean 1.74 episodes/patient/ 5 days of CGMS) and 75% of those patients experienced at least 1 asymptomatic hypoglycemic episode. There was no significant difference in the frequency of daytime versus nocturnal hypoglycemia. Hypoglycemia was more frequent in individuals on insulin (alone or in combination) (P = .02) and those on oral hypoglycemic agents (P < .001) compared to noninsulin secretagogues. CGMS analysis resulted in treatment modifications in 64% of the patients. T2DM patients on insulin exhibited higher glycemic variability (GV) scores (2.3 ± 0.6) as compared to those on oral medications (1.8 ± 0.7, P = .017). CONCLUSIONS: CGMS can provide rich data that show glucose excursions in diabetes patients throughout the day. Consequently, unwarranted onset of hypo- and hyperglycemic events can be detected, intervened, and prevented by using CGMS. Hypoglycemia was frequently unrecognized by the patients in this study (75%), which increases their potential risk of significant adverse events. Incorporation of CGMS into the routine management of T2DM would increase the detection and self-awareness of hypoglycemia resulting in safer and potentially better overall control.
BACKGROUND:Hypoglycemia is often the limiting factor for intensive glucose control in diabetes management, however its actual prevalence in type 2 diabetes (T2DM) is not well documented. METHODOLOGY: A total of 108 patients with T2DM wore a continuous glucose monitoring system (CGMS) for 5 days. Rates and patterns of hypoglycemia and glycemic variability (GV) were calculated. Patient and medication factors were correlated with rates, timing, and severity of hypoglycemia. RESULTS: Of the patients, 49.1% had at least 1 hypoglycemic episode (mean 1.74 episodes/patient/ 5 days of CGMS) and 75% of those patients experienced at least 1 asymptomatic hypoglycemic episode. There was no significant difference in the frequency of daytime versus nocturnal hypoglycemia. Hypoglycemia was more frequent in individuals on insulin (alone or in combination) (P = .02) and those on oral hypoglycemic agents (P < .001) compared to noninsulin secretagogues. CGMS analysis resulted in treatment modifications in 64% of the patients. T2DM patients on insulin exhibited higher glycemic variability (GV) scores (2.3 ± 0.6) as compared to those on oral medications (1.8 ± 0.7, P = .017). CONCLUSIONS:CGMS can provide rich data that show glucose excursions in diabetespatients throughout the day. Consequently, unwarranted onset of hypo- and hyperglycemic events can be detected, intervened, and prevented by using CGMS. Hypoglycemia was frequently unrecognized by the patients in this study (75%), which increases their potential risk of significant adverse events. Incorporation of CGMS into the routine management of T2DM would increase the detection and self-awareness of hypoglycemia resulting in safer and potentially better overall control.
Authors: Rohana J Wright; David E Newby; David Stirling; Christopher A Ludlam; Ian A Macdonald; Brian M Frier Journal: Diabetes Care Date: 2010-07 Impact factor: 17.152
Authors: Jeroen Hermanides; Titia M Vriesendorp; Robert J Bosman; Durk F Zandstra; Joost B Hoekstra; J Hans Devries Journal: Crit Care Med Date: 2010-03 Impact factor: 7.598
Authors: Danielle Hessler; Lawrence Fisher; Russell E Glasgow; Lisa A Strycker; L Miriam Dickinson; Patricia A Arean; Umesh Masharani Journal: Diabetes Care Date: 2013-10-29 Impact factor: 19.112
Authors: Janice Ms Lopez; Kathy Annunziata; Robert A Bailey; Marcia Ft Rupnow; Donald E Morisky Journal: Patient Prefer Adherence Date: 2014-05-08 Impact factor: 2.711
Authors: Denise E Bonds; Michael E Miller; Richard M Bergenstal; John B Buse; Robert P Byington; Jeff A Cutler; R James Dudl; Faramarz Ismail-Beigi; Angela R Kimel; Byron Hoogwerf; Karen R Horowitz; Peter J Savage; Elizabeth R Seaquist; Debra L Simmons; William I Sivitz; Joann M Speril-Hillen; Mary Ellen Sweeney Journal: BMJ Date: 2010-01-08
Authors: Logan Smith; Diya Chakraborty; Pallab Bhattacharya; Deepaneeta Sarmah; Sebastian Koch; Kunjan R Dave Journal: Ann N Y Acad Sci Date: 2018-06-19 Impact factor: 5.691